Church & Dwight Co., Inc. (CHD) Stock Price Today
Aura AI Summary
Key Stats
- $23.27BMarket Cap
- 1,709,766Volume
- Consumer StaplesSector
- $105.2652W High
- $81.6052W Low
- 55 DaysTypical Hold Time
- $25.27BEnterprise Value
- 1.25%Div Yield
- -Trading Activity
Track Church & Dwight Co., Inc. (CHD) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Church & Dwight Co., Inc. has traded between a low of $81.6 and a high of $105.26, highlighting its annual price range. Buy and sell Church & Dwight Co., Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Church & Dwight Co., Inc.
Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.
Most Recent News
Acoramidis shows 18% lower risk of death and hospitalizations versus tafamidis in real-world ATTR-CM study
Acoramidis, a drug for transthyretin amyloid cardiomyopathy (ATTR-CM), was linked to an 18% lower risk of death, hospitalization, and disease progression compared to tafamidis in a large U.S. electronic health record study of 2,684 patients. The stud...
Stellantis unveils six bold concept cars ahead of the Paris Motor Show, showcasing future mobility and design innovation.
Stellantis revealed six concept cars from its iconic brands at an exclusive event before the Paris Motor Show, highlighting its FaSTLAne 2030 strategy focused on innovation, customer experience, and diverse mobility solutions. These concepts, includi...
New version of Freenome's blood test shows improved detection of advanced precancerous colorectal lesions
Freenome announced improved clinical validation results for its updated SimpleScreen™ CRC blood test, showing an 18.2% sensitivity for advanced precancerous lesions (APLs), up from 13.7% in the original test. Sensitivity for high-grade dysplasia APLs...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.